What About the Children? - FDA's Response to Pediatric Drug Testing
DSpace/Manakin Repository
- DASH Home
- Harvard Law School
- HLS Student Papers
- View Item
What About the Children? - FDA's Response to Pediatric Drug Testing
| Title: | What About the Children? - FDA's Response to Pediatric Drug Testing |
| Author: | Doerner, Kristina M. |
| Citation: | What About the Children? - FDA's Response to Pediatric Drug Testing (2003 Third Year Paper) |
| Full Text & Related Files: |
Doerner.pdf (236.2Kb; PDF) 
Doerner.rtf (154.8Kb; RTF file) 
Doerner.html (111.8Kb; HTML)
|
| Abstract: | The Federal Food and Drug Administration (FDA) has played a critical role in the protection of human subjects in research. Most recently, FDA enacted an interim final rule regarding protection of children in clinical investigations. FDA’s interim rule represents its most current policy on human subject protection. Current events illuminate FDA’s policies and how FDA has chosen to respond to debates over pediatric drug testing. This paper will provide a brief history of FDA’s participation in human subject protection. This paper will then focus on FDA’s policies for pediatric research, its interim rule, and how the interim rule relates to current events. Finally, this paper will make a comment about how FDA balances its competing duties of protecting the public but also of promoting research. |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:8889476 |
This item appears in the following Collection(s)
-
HLS Student Papers [559]
HLS Student Papers
Contact administrator regarding this item (to report mistakes or request changes)
